A drug candidate for hard-to-treat cancers, developed in the Institute of Genetics and Cancer (IGC) and now licensed to Nuvectis Pharma, has moved to the next stage of clinical trials after successful completion of a dose escalation study in patients with advanced solid tumours, and a clinical drug-drug interaction study in healthy volunteers. NXP900 was developed by Professors Neil Carragher and Asier Unciti-Broceta at IGC over a period of ten years before being licensed to Nuvectis in 2021 from the University of Edinburgh in a deal facilitated by Edinburgh Innovations, the University’s commercialisation service.The drug has now moved into Phase 1b clinical trials designed to evaluate the clinical activity of NXP900 as a single agent in patients with advanced solid tumours whose cancers harbour specific genetic alterations, and in combination with EGFR and ALK inhibitors in patients with non-small-cell lung cancer whose cancers developed resistance to these treatments. We are very excited about the next phase of clinical development for NXP900 following successful completion of the Phase 1a and drug-drug interaction clinical studies led by Nuvectis, indicating that NXP900 is well tolerated, can reach therapeutic levels in cancer patients and is suitable for co-treatment in combination with other anti-cancer therapeutics. Professor Neil Carragher Personal Chair of Drug Discovery Progressing NXP900 to Phase 1b is a major milestone for the translational goals of the Institute of Genetics and Cancer. Guided by the scientific programme, including research ongoing at the IGC, the trial will explore the use of NXP900 in cancer patients with specific genetic alterations and in combination with targeted therapies in lung cancers that have developed drug resistance. Professor Asier Unciti-Broceta Personal Chair of Medicinal Chemistry Neil Carragher research group Asier Unciti-Broceta research group Tags 2025 Publication date 14 Aug, 2025
